| scholarly article | Q13442814 |
| P50 | author | Peter B. Jahrling | Q29452352 |
| Paul Whi Parren | Q38589875 | ||
| Dennis R. Burton | Q56331320 | ||
| P2093 | author name string | Toshiaki Maruyama | |
| Tom W Geisbert | |||
| P2860 | cites work | Ebola haemorrhagic fever in Zaire, 1976 | Q24650229 |
| A case of Ebola virus infection | Q24676175 | ||
| Development of a preventive vaccine for Ebola virus infection in primates | Q28140401 | ||
| Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | Q29614531 | ||
| Ebola virus can be effectively neutralized by antibody produced in natural human infection | Q30712477 | ||
| Recombinant human monoclonal antibodies to Ebola virus | Q31905799 | ||
| Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. | Q33647300 | ||
| Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | Q33853775 | ||
| The antiviral activity of antibodies in vitro and in vivo. | Q34212487 | ||
| An introduction to Ebola: the virus and the disease | Q34492420 | ||
| Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee | Q34492427 | ||
| Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections | Q34492457 | ||
| Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response | Q36231889 | ||
| Human monoclonal antibody Fab fragments cloned from combinatorial libraries: potential usefulness in prevention and/or treatment of major human viral diseases | Q36749095 | ||
| Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases | Q40424596 | ||
| Epitopes involved in antibody-mediated protection from Ebola virus | Q40625468 | ||
| Towards a vaccine against AIDS: lessons from simian immunodeficiency virus vaccines. | Q40631653 | ||
| Developing principles for emergency prevention and treatment of Ebola fever | Q40658793 | ||
| Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses | Q40674927 | ||
| Development and study of the properties of immunoglobulin against Ebola fever | Q40677969 | ||
| The isolation of hyperimmune horse serum to the Ebola virus | Q40704154 | ||
| Biologic differences between strains of Ebola virus from Zaire and Sudan | Q40838122 | ||
| Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection? | Q41717140 | ||
| Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995: determinants of survival | Q43513037 | ||
| Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. | Q43872744 | ||
| DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge | Q44089592 | ||
| Pathogenesis of experimental Ebola virus infection in guinea pigs | Q44089764 | ||
| Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections | Q44089771 | ||
| A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever | Q44089779 | ||
| Fighting the Ebola virus | Q44090031 | ||
| Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection | Q45744790 | ||
| Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants | Q45758605 | ||
| Isolation and identification of the "Marburg virus" | Q54083606 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| Orthoebolavirus zairense | Q10538943 | ||
| P304 | page(s) | 6408-6412 | |
| P577 | publication date | 2002-06-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody | |
| P478 | volume | 76 |
| Q55044697 | A Critical Domain of Ebolavirus Envelope Glycoprotein Determines Glycoform and Infectivity. |
| Q59354857 | A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus |
| Q28533408 | A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease |
| Q35980530 | A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs |
| Q34220503 | Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates |
| Q28649707 | Acquired immunity and asymptomatic reservoir impact on frontline and airport ebola outbreak syndromic surveillance and response |
| Q56535662 | Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus |
| Q34657170 | An update on the use of antibodies against the filoviruses |
| Q30148647 | Animal Models of Ebolavirus Infection |
| Q36046633 | Anti-EBOV GP IgGs Lacking α1-3-Galactose and Neu5Gc Prolong Survival and Decrease Blood Viral Load in EBOV-Infected Guinea Pigs. |
| Q30252022 | Anti-Ebola therapies based on monoclonal antibodies: current state and challenges ahead. |
| Q36583281 | Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates |
| Q28394941 | Antibodies for biodefense |
| Q34810301 | Antibodies, viruses and vaccines |
| Q92651078 | Antibody Complexes |
| Q56889146 | Antibody Repertoire of Human Polyclonal Antibodies Against Ebola Virus Glycoprotein Generated After Deoxyribonucleic Acid and Protein Vaccination of Transchromosomal Bovines |
| Q36913606 | Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site |
| Q36994087 | Antibody therapeutics for Ebola virus disease |
| Q64360579 | Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine |
| Q35955731 | Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms |
| Q58375648 | Antibody-mediated protection against Ebola virus |
| Q56999931 | Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap |
| Q35598919 | Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak |
| Q36499251 | Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses. |
| Q56763004 | Candidate medical countermeasures targeting Ebola virus cell entry |
| Q36553687 | Cell-cell contact promotes Ebola virus GP-mediated infection |
| Q45323703 | Characterization of an influenza virus pseudotyped with Ebolavirus glycoprotein |
| Q36736403 | Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies |
| Q26775792 | Clinical development of Ebola vaccines |
| Q36255716 | Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges |
| Q36043193 | Comparative Analysis of Host Cell Entry of Ebola Virus From Sierra Leone, 2014, and Zaire, 1976. |
| Q26775412 | Convalescent plasma: new evidence for an old therapeutic tool? |
| Q37945233 | Correlates of immunity to filovirus infection |
| Q33964682 | Defense against filoviruses used as biological weapons |
| Q24612811 | Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques |
| Q40327185 | Development and characterization of rabbit and mouse antibodies against ebolavirus envelope glycoproteins |
| Q56766240 | Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates |
| Q28607807 | Development of Prototype Filovirus Recombinant Antigen Immunoassays |
| Q36310674 | Development of a model for marburgvirus based on severe-combined immunodeficiency mice |
| Q36379341 | Development of treatment strategies to combat Ebola and Marburg viruses |
| Q38161994 | Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics. |
| Q44092773 | Do therapeutic antibodies hold the key to an effective treatment for Ebola hemorrhagic fever? |
| Q35842390 | Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection |
| Q26798860 | Ebola Virus Disease (The Killer Virus): Another Threat to Humans and Bioterrorism: Brief Review and Recent Updates |
| Q24629338 | Ebola haemorrhagic fever |
| Q30369241 | Ebola virus convalescent blood products: where we are now and where we may need to go. |
| Q38618148 | Ebola virus entry into host cells: identifying therapeutic strategies |
| Q33967985 | Ebola virus pathogenesis: implications for vaccines and therapies |
| Q34230491 | Ebola virus: from discovery to vaccine |
| Q27490991 | Ebolavirus glycoprotein structure and mechanism of entry |
| Q40535432 | Ectodomain shedding of the glycoprotein GP of Ebola virus |
| Q24597625 | Emerging targets and novel approaches to Ebola virus prophylaxis and treatment |
| Q30224854 | Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant |
| Q33417197 | Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus |
| Q35260239 | Evasion of the interferon-mediated antiviral response by filoviruses |
| Q36044035 | Facile Discovery of a Diverse Panel of Anti-Ebola Virus Antibodies by Immune Repertoire Mining |
| Q37463214 | Fibroblastic reticular cells and their role in viral hemorrhagic fevers |
| Q44091237 | Filoviruses: recent advances and future challenges |
| Q36305916 | Generation and characterization of protective antibodies to Marburg virus. |
| Q36033286 | Generation of Recombinant Antibodies Against Toxins and Viruses by Phage Display for Diagnostics and Therapy. |
| Q57483199 | Generation of therapeutic antisera for emerging viral infections |
| Q28741304 | H5N1 whole-virus vaccine induces neutralizing antibodies in humans which are protective in a mouse passive transfer model |
| Q47550612 | High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test |
| Q36858879 | How Ebola and Marburg viruses battle the immune system |
| Q34463780 | Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus |
| Q35793699 | Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses. |
| Q52641745 | Human transbodies that interfere with the functions of Ebola virus VP35 protein in genome replication and transcription and innate immune antagonism. |
| Q33733844 | Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus |
| Q30238887 | Immunobiology of Ebola and Lassa virus infections |
| Q35299756 | Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. |
| Q38647393 | Initiating a watch list for Ebola virus antibody escape mutations |
| Q44097842 | Long-term vaccine strategies for Ebola |
| Q64124151 | Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection |
| Q37110685 | Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. |
| Q35190882 | Monoclonal antibody specific to HA2 glycopeptide protects mice from H3N2 influenza virus infection |
| Q27011569 | Mouse models for filovirus infections |
| Q33269796 | Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys |
| Q27489891 | Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it |
| Q40105178 | New monoclonal antibodies to the Ebola virus glycoprotein: Identification and analysis of the amino acid sequence of the variable domains |
| Q56777344 | Novel neutralizing monoclonal antibodies protect rodents against lethal filovirus challenges |
| Q35802900 | Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycle |
| Q38953166 | Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes |
| Q33826350 | Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product |
| Q47548534 | Post-exposure treatments for Ebola and Marburg virus infections |
| Q35882397 | Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. |
| Q34526756 | Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference |
| Q36903111 | Potent neutralizing monoclonal antibodies against Ebola virus infection |
| Q36404178 | Potential vaccines and post-exposure treatments for filovirus infections |
| Q40044632 | Preferential production of IgM-secreting hybridomas by immunization with DNA vaccines coding for Ebola virus glycoprotein: use of protein boosting for IgG-secreting hybridoma production |
| Q28603849 | Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle |
| Q36100545 | Progress in filovirus vaccine development: evaluating the potential for clinical use. |
| Q30230272 | Progress towards the treatment of Ebola haemorrhagic fever |
| Q36088118 | Prospects for immunisation against Marburg and Ebola viruses |
| Q40552244 | Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection |
| Q40466798 | Protective efficacy of neutralizing antibodies against Ebola virus infection. |
| Q34257290 | Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever |
| Q37976671 | Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever |
| Q99637171 | Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies |
| Q36023082 | Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display. |
| Q36714652 | Status and challenges of filovirus vaccines |
| Q27014910 | Structural basis for differential neutralization of ebolaviruses |
| Q27651112 | Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor |
| Q34661120 | Structures of protective antibodies reveal sites of vulnerability on Ebola virus |
| Q40283373 | Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies |
| Q51067213 | The molecular basis of viral infection. Preface. |
| Q35941639 | The regulation and maturation of antiviral immune responses |
| Q40144389 | Therapeutics Against Filovirus Infection |
| Q36482804 | Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers |
| Q35143290 | Vaccine research efforts for filoviruses |
| Q90553223 | Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates |
| Q35693152 | Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections |
| Q40052567 | Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, non-infectious vaccine against Ebola virus challenge in mice. |
Search more.